- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Breast cancer
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1686KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 688KB)
Atezolizumab – March 2021
Atezolizumab: Solution concentrate for I.V. infusion 840 mg in 14 mL; Tecentriq®
Last updated
2 July 2021